A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Clinical Trial Grant
Administered By
Dermatology
Awarded By
AbbVie Inc.
Start Date
March 13, 2024
End Date
March 12, 2027
Administered By
Dermatology
Awarded By
AbbVie Inc.
Start Date
March 13, 2024
End Date
March 12, 2027